Video Library

How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.
The Use of Next-Generation Sequencing in Treating Non-Squamous Non-Small-Cell Lung Cancer
Drs. Goeffrey Oxnard and Lauren Ritterhouse consider how next-generation sequencing (NGS) informs treatment of lung cancer patients in providing information on tumor mutational burden, microsatellite instability, unique targetable genomic signatures, as well as novel targets that may be best addressed in a clinical trial.
How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer
Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
Accurate and Reproducible Measurement of PD-1/PD-L1
Drs. Geoff Oxnard and Lauren Ritterhouse discuss PD-1/PD-L1 as a routine biomarker test run on all lung cancer biopsy specimens, as well as on other selected cancer types, and how qualitative and quantitative results are typically reported.
How Molecular Biomarkers Have Impacted Cancer Treatment
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges and opportunities of precision medicine and molecular biomarkers in their clinical practice from an oncologist’s and a pathologist’s perspective.
Optimizing Communication Between Oncologists and Pathologists on Cancer Biomarker Testing
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the best ways oncologists and pathologists can communicate about molecular biomarker testing for individual patients as well as on strategies for incorporating new biomarkers into testing panels.
How the Treatment of Lung Cancer Has Been Transformed in the Era of Molecular Biomarker Testing
Drs Roy Herbst and David Rimm review how biomarker testing has transformed the way patients with lung cancer are treated, and how both medical oncologists and pathologists contribute to these changes.
How to Foster Communication Among all Members of the Cancer Care Team with Pathologists to Deliver Individualized Treatment for Patients with Lung Cancer
Drs Roy Herbst and David Rimm consider novel ways that surgeons, interventional radiologists, pulmonologists, medical oncologists, and pathologists interact at Yale Cancer Center to maximize the use of common molecular biomarkers, as well as NGS and TMB, in providing precision medicine to lung cancer patients.
AONN+ Standardized Metrics and the Biden Cancer Initiative
Danielle Carnival recognizes that data standardization is a huge problem in cancer care, and notes that the AONN+ standardized navigation metrics are a giant step toward making progress in this area.
The Biden Cancer Initiative Fierce Awards
Danielle Carnival talks about the Fierce Awards, which aim to recognize the unsung heroes in the cancer community and introduce them to a wider audience.
How to Get Involved in the Biden Cancer Initiative
The Biden Cancer Initiative relies on the expertise of those involved in cancer care, and as such, is looking for input from navigators.
Navigators Are a Great Example of How the System Should Be Designed
As Vice President of the Biden Cancer Initiative, Danielle Carnival recognizes that navigators are an essential part of the care system in oncology. Hear why.
Page 8 of 10
Results 85 - 96 of 114

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country